+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Chronic Myelogenous Leukemia Therapeutics Market Research Report by Tyrosine Kinase Inhibitors, Distribution Channel, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

  • PDF Icon

    Report

  • 155 Pages
  • January 2023
  • Region: United States
  • 360iResearch™
  • ID: 5721605
The United States Chronic Myelogenous Leukemia Therapeutics Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Chronic Myelogenous Leukemia Therapeutics Market.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Chronic Myelogenous Leukemia Therapeutics Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Chronic Myelogenous Leukemia Therapeutics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Chronic Myelogenous Leukemia Therapeutics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Chronic Myelogenous Leukemia Therapeutics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Chronic Myelogenous Leukemia Therapeutics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Tyrosine Kinase Inhibitors, the market is studied across Antimetabolites, Asciminib, Bosutinib, Dasatinib, Nilotinib, and Ponatinib.
  • Based on Distribution Channel, the market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Chronic Myelogenous Leukemia Therapeutics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Chronic Myelogenous Leukemia Therapeutics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Chronic Myelogenous Leukemia Therapeutics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Chronic Myelogenous Leukemia Therapeutics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Chronic Myelogenous Leukemia Therapeutics Market, including Abbvie Inc., Amneal Pharmaceuticals LLC, Bristol Myers Squibb Company, F. Hoffmann La Roche Ltd., Ilyang Pharmaceutical Co. Ltd., Incyte Corporation, Innovent Biologics Inc., Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Chronic Myelogenous Leukemia Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Chronic Myelogenous Leukemia Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Chronic Myelogenous Leukemia Therapeutics Market?
4. What is the competitive strategic window for opportunities in the United States Chronic Myelogenous Leukemia Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the United States Chronic Myelogenous Leukemia Therapeutics Market?
6. What is the market share of the leading vendors in the United States Chronic Myelogenous Leukemia Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the United States Chronic Myelogenous Leukemia Therapeutics Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High incidence and prevalence of chronic myeloid leukemia
5.1.1.2. New approaches and treatment combinations for the management of chronic myeloid leukemia
5.1.2. Restraints
5.1.2.1. High-cost of treatment
5.1.3. Opportunities
5.1.3.1. Advancement in drug development for myeloid leukemia
5.1.3.2. Rising awareness programs regarding myeloid leukemia treatment
5.1.4. Challenges
5.1.4.1. Complications related to chemotherapy
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Chronic Myelogenous Leukemia Therapeutics Market, by Tyrosine Kinase Inhibitors
6.1. Introduction
6.2. Antimetabolites
6.3. Asciminib
6.4. Bosutinib
6.5. Dasatinib
6.6. Nilotinib
6.7. Ponatinib

7. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies

8. California Chronic Myelogenous Leukemia Therapeutics Market
8.1. Introduction

9. Florida Chronic Myelogenous Leukemia Therapeutics Market
9.1. Introduction

10. Illinois Chronic Myelogenous Leukemia Therapeutics Market
10.1. Introduction

11. New York Chronic Myelogenous Leukemia Therapeutics Market
11.1. Introduction

12. Ohio Chronic Myelogenous Leukemia Therapeutics Market
12.1. Introduction

13. Pennsylvania Chronic Myelogenous Leukemia Therapeutics Market
13.1. Introduction

14. Texas Chronic Myelogenous Leukemia Therapeutics Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbvie Inc.
16.2. Amneal Pharmaceuticals LLC
16.3. Bristol Myers Squibb Company
16.4. F. Hoffmann La Roche Ltd.
16.5. Ilyang Pharmaceutical Co. Ltd.
16.6. Incyte Corporation
16.7. Innovent Biologics Inc.
16.8. Lupin Ltd.
16.9. Merck KGaA
16.10. Novartis AG
16.11. Pfizer Inc.
16.12. Sanofi S.A.
16.13. Sun Pharmaceutical Industries Ltd.
16.14. Takeda Pharmaceutical Co. Ltd.
16.15. Teva Pharmaceutical Industries Ltd.
16.16. Viatris Inc.

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TYROSINE KINASE INHIBITORS, 2030
FIGURE 12. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
FIGURE 13. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ASCIMINIB, 2018-2030 (USD MILLION)
FIGURE 14. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, 2018-2030 (USD MILLION)
FIGURE 15. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, 2018-2030 (USD MILLION)
FIGURE 16. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, 2018-2030 (USD MILLION)
FIGURE 17. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, 2018-2030 (USD MILLION)
FIGURE 18. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 19. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2030
FIGURE 21. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 22. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 23. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
FIGURE 24. CALIFORNIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 25. FLORIDA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 26. ILLINOIS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 27. NEW YORK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 28. OHIO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 29. PENNSYLVANIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 30. TEXAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 31. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 32. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 33. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 5. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 6. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
TABLE 7. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY STATE, 2018-2030 (USD MILLION)
TABLE 8. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ASCIMINIB, 2018-2030 (USD MILLION)
TABLE 9. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ASCIMINIB, BY STATE, 2018-2030 (USD MILLION)
TABLE 10. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, 2018-2030 (USD MILLION)
TABLE 11. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY BOSUTINIB, BY STATE, 2018-2030 (USD MILLION)
TABLE 12. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, 2018-2030 (USD MILLION)
TABLE 13. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DASATINIB, BY STATE, 2018-2030 (USD MILLION)
TABLE 14. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, 2018-2030 (USD MILLION)
TABLE 15. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY NILOTINIB, BY STATE, 2018-2030 (USD MILLION)
TABLE 16. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, 2018-2030 (USD MILLION)
TABLE 17. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PONATINIB, BY STATE, 2018-2030 (USD MILLION)
TABLE 18. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 19. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 20. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 21. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 22. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY STATE, 2018-2030 (USD MILLION)
TABLE 25. CALIFORNIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 26. CALIFORNIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 27. CALIFORNIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. FLORIDA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 29. FLORIDA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 30. FLORIDA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. ILLINOIS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 32. ILLINOIS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. ILLINOIS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. NEW YORK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 35. NEW YORK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 36. NEW YORK CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. OHIO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 38. OHIO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 39. OHIO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. PENNSYLVANIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 41. PENNSYLVANIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. PENNSYLVANIA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. TEXAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 44. TEXAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 45. TEXAS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 47. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 48. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 49. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 50. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 51. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 52. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 53. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 54. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 55. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 56. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 57. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbvie Inc.
  • Amneal Pharmaceuticals LLC
  • Bristol Myers Squibb Company
  • F. Hoffmann La Roche Ltd.
  • Ilyang Pharmaceutical Co. Ltd.
  • Incyte Corporation
  • Innovent Biologics Inc.
  • Lupin Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Methodology

Loading
LOADING...